Management of benign prostatic hyperplasia with silodosin

about

Management of benign prostatic hyperplasia with silodosin

Item

http://www.wikidata.org/entity/Q38160469

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of benign prostatic hyperplasia with silodosin

@en

type

Item

label

Management of benign prostatic hyperplasia with silodosin

@en

prefLabel

Management of benign prostatic hyperplasia with silodosin

@en

P1476

Management of benign prostatic hyperplasia with silodosin

@en

P2093

Ken-Ichiro Yoshida

http://www.w3.org/2001/XMLSchema#string

Ryuji Sakakibara

http://www.w3.org/2001/XMLSchema#string

Takao Kamai

http://www.w3.org/2001/XMLSchema#string

Tomonori Yamanishi

http://www.w3.org/2001/XMLSchema#string

Tomoya Mizuno

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Uchiyama

http://www.w3.org/2001/XMLSchema#string

P2860

Intraoperative floppy iris syndrome associated with tamsulosin

alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

Expression of heat shock protein 70 and its mRNAs during ischemia-reperfusion in the rat prostate.

Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet obstruction.

Transurethral holmium: YAG laser prostatectomy using a side-firing fiber for bladder outlet obstruction due to benign prostatic enlargement: urodynamic evaluation of surgical outcome.

Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention.

Holmium laser for benign prostatic hyperplasia.

Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age.

KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/RRU.S5004

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24198606

http://www.w3.org/2001/XMLSchema#string

P932

3806400

http://www.w3.org/2001/XMLSchema#string